Darpp32; DARPP-32; Dopamine and adenosine 3′,5′-monophosphate-regulated phosphoprotein, 32 kDa; Dopamine and cAMP-regulated phosphoprotein; Dopamine- and cAMP-regulated phosphoprotein, Mr32 kDa; Ppp1r1b; Protein phosphatase 1 DARPP-32 inhibitor protein; Protein phosphatase 1, regulatory (inhibitor) subunit 1B
Recent studies using behavioral analysis of animal models suggest that alterations in critical intracellular signaling pathways have an important role in the pathophysiology and treatment of complex neuropsychiatric disorders. The hypothesis is that, if the vast majority of psychiatric medications exert their primary therapeutic actions in the first week of treatment, the therapeutic effects involve transcriptional changes initiated and maintained by critical intracellular signaling pathways.
The dopaminergic neurotransmission system has been the focus of much research throughout the last few decades, including psychiatric and neurological...
- Ehrman LA, Williams MT, Schaefer TL, et al. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav. 2006;5(7):540–51.PubMedCrossRefGoogle Scholar
- Ishikawa M, Mizukami K, Iwakiri M, Asada T. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiat. 2007;31(6):1177–81.CrossRefGoogle Scholar